Viking Therapeutics: Canaccord sees 194% price potential referencing potential obesity drugs
Reading Time: 3 minutes
Viking Therapeutics (VKTX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. The company targets two so-called "blockbuster markets" with high medical need. In its pipeline, for example, is the weight loss drug VK2735 (the "Turbo Appetite Suppressant”). VK2735 is a "dual agonist" for the GLP-1 and GIP receptors. This means it mimics the action of two natural gut hormones responsible for the feeling of fullness and the regulation of blood sugar. This leads to significant...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
